MedTrace Logo

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

NCT04336241 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-02-27

No results posted yet for this study

Summary

RP2-001-18 is a Phase 1, multicenter, open label, single agent dose escalation and combination treatment study of RP2 in adult subjects with advanced solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.

Conditions

Interventions

BIOLOGICAL

RP2

Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation

BIOLOGICAL

nivolumab

Programmed death receptor (PD-1) blocking antibody

Sponsors & Collaborators

  • Replimune Inc.

    lead INDUSTRY

Principal Investigators

  • Gary Vanasse, MD · Replimune Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-17
Primary Completion
2026-10-31
Completion
2026-10-31

Countries

  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04336241 on ClinicalTrials.gov